Last reviewed · How we verify
Hydroconquinine (HYDROQUINIDINE)
Hydroquinidine works by blocking potassium channels in the heart to help regulate heart rhythm.
Hydroquinidine is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a hydroquinidine and its mechanism of action involves blocking potassium channels, which can help regulate heart rhythm. However, its commercial status and approved indications are unknown. As a result, its availability and use are limited. Further research is needed to determine its potential as a therapeutic agent.
At a glance
| Generic name | HYDROQUINIDINE |
|---|---|
| Drug class | hydroquinidine |
| Target | Sodium channel subunit beta-1, Sodium channel subunit beta-2, Sodium channel subunit beta-3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Think of your heart like a pump that beats at a certain rate. Potassium channels help control how fast the heart beats. Hydroquinidine blocks these channels, which can help slow down an irregular heartbeat and make it more regular.
Approved indications
Common side effects
Key clinical trials
- Empiric Quinidine for Asymptomatic Brugada Syndrome (PHASE2,PHASE3)
- Hydroquinidine Versus Placebo in Patients With Brugada Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |